摘要
目的:系统评价健脾益气化瘀解毒法(JPHYJD法)治疗慢性萎缩性胃炎(CAG)伴胃癌前病变(GPL)的疗效及安全性。方法:计算机检索国内外相关数据库,查找JPHYJD法治疗CAG-GLP的随机对照试验相关文献,采用Rev Man 5.3软件进行Meta分析。结果:共纳入合格文献32篇,共2 662例患者。Meta分析结果:JPHYJD法治疗CAG-GLP临床疗效方面、胃镜疗效、抗Hp有效率等方面优于单纯应用西药常规治疗,其差异均有统计学意义(P<0.00001);在改善胃痛、痞满、纳差、恶心、嗳气及安全性方面,JPHYJD法疗效亦优于西药常规治疗。结论:现有相关数据表明,JPHYJD法治疗CAG-GLP较单纯应用西药治疗临床疗效更好,胃镜疗效显著,能更有效抗Hp治疗,由于本Meta分析纳入研究较少,证据强度有限,上述结论仍需更多高质量研究加以验证。
Objective: To evaluate the effectiveness and safety of the Jianpi Yiqi Huayu Jiedu method(JPHYJD) in the treatment of chronic atrophic gastritis with gastric precancerous lesions(CAG-GPL). Methods: All the papers concerning CAGGPL treated by purely Chinese herbal medicine intervention and controlled with western medicine intervention were collected. Metaanalysis was performed by the statistical software Rev Man 5.3. Results: Thirty-two RCTs including 2 662 patients accorded with criteria were included, and these trials were all made in China. Compared with western medicine, Chinese herbal medicine(JPHYJD)or its combination with other conventional western medicine were more effective in improving clinical efficacy, endoscopic efficacy, anti-Hp efficiency and other aspects in the treatment of CAG-GPL, and the difference was statistically significant(P<0.00001). Conclusion: The therapeutic effect of Chinese herbal medicine(JPHYJD) or its combination with other conventional western medicine are more effective in clinical efficacy, endoscopic efficacy and anti-Hp efficiency than western medicine. Since this Metaanalysis is less involved and the evidence intensity is limited, the above conclusions are still validated by more high-quality studies.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2017年第11期5122-5128,共7页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金项目(No.81673946
No.81273739)
广东省知识产权局软科学研究计划项目(No.GDIP2016-G3)
广东省省级科技计划项目(No.2015A070703015)~~
